Professor Tobias Arkenau is a renowned Consultant Medical Oncologist with HCA Healthcare at numerous locations including Sarah Cannon Research Institute, The Harley Street Clinic, The Princess Grace and The Wellington Hospital. Additionally, he holds an NHS post at University College London Hospital where he is a Professorial Research Associate.

He is a founding Medical Director of the Sarah Cannon Research Institute UK and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the HCA Healthcare UK Cancer Service Line. The talented physician has a wide range of experience in a variety of cancers, particularly gastrointestinal and skin cancers.

He was awarded his medical degree from Hanover Medical School in Germany in 2000. Following this, he completed his specialist training in oncology across numerous centres of excellence including the Royal Marsden Hospital. He was awarded a Fellowship by the Royal College of Physicians, and he is a key opinion leader in his field of Gastrointestinal Cancers, Drug Development and Immunotherapy for his reserach contributions to his field. During his career, he has published numerous peer reviewed articals and book chapters and contributes regulalry at international meetings such as ASCO, ESMO and AACR. He is leading the Sarah Cannon Institute UK as a Chief and Principal Investigator of numerous clinical trials of new anti-cancer drugs including immunotherapies and cellular therapies.

Diseases, Medical Tests and Treatments

• Immunotherapy
• Chemotherapy
• Clinical Trials, Phase-1 studies
• Drug Development, Experimental Therapies
• TIL-Therapy
• Biological Therapy
• Video Consultation
• Genetic Testing (Genomics Review Board)
• Gastrointestinal Cancer
• Skin Cancer
• Upper Gastrointestinal Cancer
• Lower Gastrointestinal Cancer
• Melanoma
• Bile Duct Cancer
• Bowel Cancer
• Colon Cancer
• Gallbladder Cancer
• Liver Cancer
• Oesophagus Cancer
• Pancreatic Cancer
• Stomach Cancer
• Small Bowel Cancer

Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. Since then he has been working in cancer care, training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. During this time, he achieved a PhD at the Institute for Cancer Research, London, and was awarded the EORTC-PAMM Young Investigator Award in 2004. He completed his specialist training in Medical Oncology in 2008 and was appointed as a UCL Clinical Senior Lecturer and UCH Consultant in Medical Oncology in 2009. Since then he has been running a research-based practice and has been principal/chief investigator for more than 20 early and late phase clinical trials.

Martin is involved in the management of patients with both lung and head and neck cancers. He is interested in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He has a particular interest in cancer biology that leads to the development of both lung and head and neck cancers.

• Chemotherapy

• Lung and head and neck cancers
• Drug development 
• Cancer biology

Professor John Bridgewater is a Consultant Medical Oncologist and Clinical Researcher at the UCL Cancer Institute. He specialises in gastrointestinal oncology, with a particular interest in biliary tract cancers and carcinomas of unknown primary origin.

After studying medicine at Oxford and University College London, he went on to specialise in Medical Oncology at the Middlesex, Mount Vernon and Royal Marsden Hospital. He was awarded a PhD by the Institute of Cancer Research for research into gene therapy. In 1999 he was appointed as a Senior Lecturer in Medical Oncology at UCL.

Professor Bridgewater leads the National Cancer Research Institute subgroup in hepatobiliary malignancy and also has a laboratory programme at the UCL Cancer Institute investigating carcinoma of unknown primary origin. He is also active in trials across the gastrointestinal portfolio and has been the chief investigator on a number of landmark studies into gastrointestinal and biliary tract cancers. As well as his clinical and research work, he also serves on a number of committees including The National Institute for Health and Care Excellence (NICE) and National Cancer Research Institute (NCRI). 

• Chemotherapy 

• Bilary Cancer 
• Bowel Cancer 
• Cancer Unknown Primary
• Gastro-intestinal Cancers
• Liver Cancer 

Dr Naomi Fersht is a consultant clinical oncologist at University College Hospital and the National Hospital for Neurology and Neurosurgery. She specialises exclusively in the management of primary and secondary brain and spinal tumours. This involves the use of both conventional and innovative radiotherapy techniques and chemotherapy.

Her special interests are brain oligometastases; meningiomas; pituitary tumours; the management of teenagers and young adults with brain tumours; and advanced radiotherapy techniques including radiosurgery.

She qualified from the University of Cambridge and her specialist training was at the Royal Marsden and University College Hospitals. Naomi's doctoral thesis, supervised by Nobel Laureate Sir Paul Nurse, was in cell cycle checkpoints.

• Brain oligometastases
• Meningiomas
• Pituitary tumours
• The management of teenagers and young adults with brain tumours (age 16-24)
• Advanced radiotherapy techniques including radiosurgery

Mr Myles Smith is a Consultant Surgical Oncologist and General Surgeon currently based at the private practices Lister Hospital, Chelsea Output Centre, and Chiswick Medical Centre. His current post is the Royal Marsden Hospital, Fulham Road. He has a special interest in surgery for soft tissue sarcoma and melanoma, in particular retroperitoneal, pelvic and intra-abdominal sarcomas as well as anorectal and visceral melanoma.

Mr Smith qualified in Medicine at National University of Ireland 1998 with Bachelor of Medicine, Bachelor of Surgery degrees. He the trained as a General Surgeon with a specialist interest in colorectal surgery. He went on to complete his PhD with the University College Cork and underwent additional specialist training in General Surgical Oncology, as a fellow at the University of Toronto.

In addition, Mr Smith is board certified in surgical oncology and in 2014 received the top score in the UEMS European Board of Surgery Qualification Surgical Oncology Exams (EBSQ). He is also interested in research, has professional publications and offers courses to GPs. 

• Diagnosis of a lump
• Skin cancer surgery
• Lipoma surgery
• Sebcaceous cyst surgery
• Basal Cell Carcinoma
• Squamous Cell Carcinoma
• Melanoma
• Melanoma Wide Local Excision
• Melanoma Sentinel Node Biopsy
• Lymph node surgery for melanoma and skin cancer
• Robotic Surgery
• Open Hernia Repair
• Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)
• GIST surgery
• Retroperitoneal Tumour Surgery
• Colorectal surgery
• Endocrine surgery
• Upper gastrointestinal surgery

• Soft Tissue Sarcoma
• Melanoma
• Advanced skin cancer
• SCC
• BCC
• DFSP
• GIST
• Anorectal and Visceral Melanoma
• Appendicitis
• Benign Anorectal Disease
• Hernia (Inguinal and Ventral)
• Leiomyosarcoma
• Inguinal hernia
• Pelvic Tumours
• Retroperitoneal Sarcoma
• Soft Tissue Sarcoma
• Solitary Fibrous Tumours
• Small Bowel Tumours
• Adrenal gland tumours
• Pheochromocytoma

Dr Tom Richards is a consultant clinical oncologist specialising in the treatment of gastrointestinal (GI) and breast cancers. He is the clinical lead of the GI and breast cancer radiotherapy units at University College London NHS Hospital (UCLH) and honorary consultant in Clinical Oncology at The Whittington NHS Hospital. Prior to his appointment at UCLH, he was Clinical Oncology consultant in the GI and breast units at St Bartholomew's and The Royal London NHS Hospitals.

He is an experienced oncologist treating oesophagus, stomach, liver, pancreaticobiliary, colorectal and breast cancers. His specialist expertise is the delivery of radiotherapy, chemotherapy and biological targeted drugs for cancers at these sites. His particular interest is in technical radiotherapy treatments using cyberknife and intensity-modulated radiotherapy and motion management techniques using 4D-CT radiotherapy planning, deep inspiratory breath-hold and image-guided radiotherapy.

After graduation from Imperial College School of Medicine in London, his subsequent general internal medicine training was at King's College Hospital, London. He undertook specialist oncology training at St Bartholomew's and The Royal Marsden Hospitals in London. In 2015 he was awarded a PhD from the University of London for clinical and translation research performed at The Institute of Cancer Research, King's College London and The Royal Marsden Hospital. He studied the mechanisms by which therapeutic radiation affects normal tissues and strategies to detect and reduce late toxicity after curative treatment. He was awarded the Johnson and Johnson clinical research prize in 2012 for work contributing to his PhD.

He is a fellow of the Royal College of Radiologists and a member of The Royal College of Physicians, ESMO and ESTRO. He has spoken and chaired sessions at numerous national and international meetings. He is course tutor and examiner for the Institute of Cancer research MSc course and is the local principal investigator for several GI cancer clinical trials. Dr Richards is passionate to improve cancer outcomes, develop clinical research and deliver innovative multi-modality cancer treatments.

• Radiotherapy
• Chemotherapy
• SABR/Cyberknife
• Intensity-modulated radiotherapy
• SIRT (internal liver-directed radiotherapy)

• Breast cancer
• Colon cancer
• Rectal cancer
• Anal cancer
• Oesophageal cancer
• Liver cancer
• Pancreatico-biliary cancer

Professor Nutting is providing COVID-safe telephone and video consultations for cancer patients requiring a second opinion during this difficult time.

Professor Christopher Nutting is a Consultant Clinical Oncologist based at The Royal Marsden Chelsea and Sutton, where he has both a private and NHS practice. 

Professor Nutting completed his undergraduate training at the University of London in 1992 and he went on to become a member of the Royal College of Physicians and a Fellow of the Royal College of Radiologists. Professor Nutting qualified as an oncologist and achieved a Medical Doctorate at The Institute of Cancer Research, University of London.

Professor Nutting has a special interest in medical education and in 2001 he was appointed Honorary Senior Lecturer in Clinical Oncology at The Institute of Cancer Research. In 2002 he assumed the role of Teacher at the University of London and Head of the Head and Neck Unit at The Royal Marsden.

Professor Nutting is National Clinical Lead in Head and Neck Cancer for the UK Department of Health and the Cancer Services Collaborative. He is also President of the British Oncological Association and Chairman of the National Cancer Research Institute Committee for Head and Neck Cancer Research.

Professor Nutting is heavily involved in research trials and he has published over 300 research articles in his speciality.

• Chemotherapy
• Radiotherapy
• Intensity-modulated radiotherapy
• Radioiodine treatment
• Cyberknife

• Head and neck cancers
• Mouth cancer
• Throat cancer
• Thyroid cancer
• Lung cancer
• Skin cancer

Dr Hadaki is an experienced Consultant Oncologist who treats all stages of breast cancer.

He completed his specialist oncology training at Addenbrooke’s Teaching Hospital which has strong affiliations to the University of Cambridge. During his training, he completed the Royal College of Radiologist membership exam to proudly become one of its fellowships.

Dr Hadaki has been practising as a consultant since 2012 and has a very successful private practise in addition to his large well-established NHS practice.

Dr Hadaki is skillfully able to combine (where appropriate) the following treatment modalities to offer a complete and state of the art personalised cancer treatment service:

• Chemotherapy
• External beam radiotherapy (including IMRT and IGRT)
• Biological and targeted therapies
• Immunotherapies
• Stereotactic radiotherapy (SBRT, SABR, Cyberknife)
• Next-generation sequencing and molecular analysis of tumours
• Chemotherapy sensitivity testing
• Access to clinical trials
• Access to local ablative therapies (radiofrequency ablation, microwave ablation)
• Access to alternative therapies
• Access to palliative care services

Dr Hadaki also works with some of the most skilled surgeons in the country. All treatment plans are discussed at multidisciplinary team meetings.

Dr Hadaki is registered and compliant with the majority of private medical insurers including BUPA, BUPA International, AXA, Aviva, Vitality, WPA and others.

Dr Hadaki is able to treat international and self-paying patients. Embassy sponsored patients must have a letter of guarantee before any consultation or commencing treatment.

Self-paying patients should contact us directly for a quotation.

• Breast Cancer
• Lung Cancer
• Chemotherapy
• Immunotherapy
• Radiotherapy
• Stereotactic ablative radiotherapy (SABR)
• Oncology

• Breast Cancer

Dr Gregory Wilson is a Consultant Medical Oncologist, based in Manchester at The Christie NHS Foundation Trust. Dr Wilson also sees patients privately at a range of centres, both in the north west and in London. His interests include breast and colorectal cancer and he has a particular focus on metastatic diseases and patients with liver metastases. Dr Wilson is the Lead Clinician for liver-directed therapies and he provides The Harley Street Clinic with both an advisory and visiting clinical service. He works closely with consultant oncology, surgery and radiology colleagues to provide liver-directed therapies for patients of the Harley Street Clinic and The London Oncology Clinic.

He advises on a range of treatment options including Selective Internal Radiation Therapy, Chemotherapy Saturation of the liver and DC beads, a novel drug delivery embolisation system for tumours in the liver. Dr Wilson is a member of the breast and gastrointestinal disease groups of The Christie Hospital and takes an active role in recruiting patients onto national and international clinical research trials of newer treatment regimes.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Chemotherapy
• Biological Therapy
• Radiotherapy

• Breast Cancer
• Colorectal Cancer
• Liver Cancer

Dr Peter Harper trained at University College and University College Hospital (MB BS 1970) and has been a leading consultant at Guy's and St Thomas Hospital for over 25 years. He is both an accredited physician and a medical oncologist. One of the four founder partners of the London Oncology Clinic, his vision was of a clinic dedicated solely to cancer treatment offering the highest international standards of care in a state-of-the-art supportive environment, also providing the support including all the ancillary care required by patients and their families.

Author of more than 400 papers and chapters in peer-reviewed publications, he is acknowledged globally for his work in researching new drugs and developing improved forms of cancer treatment. He has been the chair, or has been a member of many international executive committees investigating new approaches to cancer treatment, editorial boards for professional publications and is currently a member of eight pharmaceutical company advisory boards and is a member of sixteen professional bodies from around the world, including board membership of a committee of the American Society of Clinical Oncologists (ASCO).

In 2002 he was awarded the prestigious Cino del Duca Medal in 2004 in recognition of his work in developing new anti-cancer and vaccine therapies. For his role in advising the French Government in strategic cancer care (Board Member French National Cancer Institute), he was appointed a Chevalier of the Legion D'Honneur, a rare distinction for a foreign national. He remains on the board of INCA, the strategic committee for cancer treatment in France, and is currently the Chairman of the Toulouse Cancer Centre and holds the Medaille D'Or of that city.

• Chemotherapy of solid tumours
• Gynaecological cancers
• Gastrointestinal cancers
• Breast cancer
• Lung cancer
• Urological cancers

• Chemotherapy of solid tumours
• Gynaecological cancers
• Gastrointestinal cancers
• Breast cancer
• Lung cancer
• Urological cancers